Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2021-11-02 Director's Dealing
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Mandatory notification of intra group transfer of shares by primary insider’s related party
Director's Dealing Classification · 98% confidence The document explicitly states it is a 'Mandatory notification of intra group transfer of shares by primary insider’s related party'. It details the sale of shares between related entities controlled by a primary insider (Christian Åbyholm, a board member). This type of transaction, involving personal share dealings by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). The document is short and reports a specific transaction involving insider holdings, not a general financial report.
2021-11-02 English
Registration of new share capital
Share Issue/Capital Change Classification · 98% confidence The document explicitly states 'Registration of new share capital' and details the resulting new share capital amount and total number of shares following the exercise of employee share options. This directly relates to a change in the company's capital structure, specifically the issuance of new shares. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). The document is short and appears to be a formal announcement of this change.
2021-11-01 English
Share capital increase from exercise of warrants
Share Issue/Capital Change Classification · 98% confidence The document explicitly states the subject is a 'Share capital increase from exercise of warrants'. It details the resulting change in share capital (from NOK 2,870,117.09 to NOK 2,871,817.10) and the increase in the number of outstanding shares (from 287,011,709 to 287,181,710) due to the exercise of warrants by an employee. This directly relates to changes in the company's capital structure and share count, matching the definition for 'Share Issue/Capital Change' (SHA). The document length is very short (504 chars), but it is a direct announcement of the capital change itself, not an announcement *about* a report, making SHA more appropriate than RPA or RNS.
2021-10-29 English
Mandatory notification of intra group transfer of shares by primary insider’s related party
Director's Dealing Classification · 98% confidence The document details transactions involving shares of Vaccibody AS conducted by a person discharging managerial responsibilities (Einar J. Greve, Board Member). Specifically, it reports the 'Sale of shares to closely associated enterprise' and the subsequent 'Acquisition of shares from closely associated enterprise' involving WEP AS/Cipriano AS. This structure—reporting personal transactions by directors/executives—is characteristic of insider dealing notifications. The closest matching category is 'Director's Dealing' (DIRS).
2021-10-14 English
Mandatory notification of intra group transfer of shares by primary insider’s related party
Director's Dealing Classification · 98% confidence The document text explicitly states it is a "Mandatory notification of intra group transfer of shares by primary insider’s related party." It details a transaction involving shares by a related party of a board member (Einar J. Greve). This type of transaction report, detailing personal share transactions by directors or related parties, aligns directly with the definition of Director's Dealing (DIRS). Although the text mentions an 'attached document', the core content is the notification itself, which is specific enough to avoid the general RPA/RNS fallback. The transaction involves an insider's related party, fitting the scope of DIRS.
2021-10-14 English
Mandatory notification of intra group transfer of shares by primary insider’s related party
Director's Dealing Classification · 99% confidence The document details transactions involving shares of Vaccibody AS conducted by a person discharging managerial responsibilities (Lars Lund-Roland, Board Member). Specifically, it reports the 'Sale of shares to closely associated enterprise' and 'Acquisition of shares from closely associated enterprise' on 12.10.2021. This type of mandatory disclosure concerning personal share transactions by directors and executives is classified as Director's Dealing.
2021-10-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.